NorthWest Biotherapeutics Inc (NWBO)

[Red_Right_Hand]

Beartrap, to your point, the P2 polyICLC combo trial (NCT01204684) set out to enroll 60 patients, with the goal of measuring "Time to tumor progression and overall survival" over a 2-year period.

In January 2015, the Overall Status was changed from Recruiting -> Active, Not Recruiting. So if they stopped Recruiting in 2015, and they intended to follow patients for a 2-year period after treatment, why is the Primary Completion Date listed as January 2024 (i.e, 5 months from now)? It would seem the planned 2-year follow-up from the last recruited patient would've been completed no later than sometime in 2018. Or are they waiting for the OS tail to mature beyond the 2-year follow-up?

They'd be beyond 5 years from final patient recruitment at this point.